PRVA — Stock Film
STOCK FILMSCENE 1/11PRVA · $20.42
Stock Expert AI presents
PRVA
Privia Health Group, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Privia Health Group, Inc. What it actually does.

Privia Health operates as a physician-enablement company. They collaborate with medical groups, health plans, and health systems. Now — the numbers.

on the stock market since 2021
1,226 employees
$2.6B market value
WHERE DOES THE MONEY COME FROM?
64%FFS-Patient Care
FFS-Patient CareCapitated Revenue 15%Shared Savings 11%FFS-Administrative Services 6%Care Management Fee (PMPM) 3%Other <1%
64% of all revenue comes from a single line: FFS-Patient Care.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Revenue last year:
$2.1B
The net profit left over:
$22.9M
Out of every $100 in sales, $1 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 1%

This is an established company with proven profits.

THE SALES TREND
Sales are growing, year after year.

Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.

$966.2M
2021
2022
2023
2024
$2.1B
2025
Cash on hand:
$479.7M
Total debt:
$9.5M
The cash outweighs the debt.

If every debt were paid off today, $470.2M would still be left in the vault — a solid cushion for hard times.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
59
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
44
weak

Clearly below the class average.

VALUATION
66
strong

Clearly above the class average — a step short of the very top.

GROWTH
89
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
42
weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 52% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
Sales keep climbing

Over the last 4 years, sales grew about 22% a year on average.

2
THE BRIGHT SIDE · 2/2
Strong cash, light debt

There is $479.7M in the vault; even if every debt were paid off, $470.2M would remain.

1
THE RISKS · 1/3
A rich price tag

The company’s market value is 112 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 42/100. For a turnaround signal, the stock first needs to close the gap with the market.

3
THE RISKS · 3/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 44/100.

FINALE · THE GRADE
D
35 / 100 · MoonshotScore

On our five-subject report card, PRVA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: PRVA does earn real profits — but on our report card it still sits behind its class. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film